This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Interventions
Two separate comparisons were considered: a combination of metformin plus saxagliptin was compared against metformin plus insulin in patients who failed metformin monotherapy; and a combination of sulphonylurea plus saxagliptin was compared against sulphonylurea plus insulin in patients who failed sulphonylurea monotherapy.
Location/setting
Poland/primary care.
Methods

Analytical approach:
The analysis was based on the published and validated Cardiff Diabetes Model that simulates management of diabetic patients over a time horizon of 40 years. The authors stated that the perspective was that of the Polish National Health Fund.
Effectiveness data:
A selective approach was used to identify relevant sources of evidence. Most data had been already incorporated in the model and were based on evidence from the United Kingdom Prospective Diabetes Study (UKPDS). Additional data taken from country-specific sources and published studies were used to populate the model. Efficacy of treatment in terms of change in HbA1c and body weight was a key input of the model and was taken from several studies including a meta-analysis of 14 clinical trials and a systematic review. No head-to-head studies were available.
Monetary benefit and utility valuations:
Utility valuations were derived from published sources. Most data were taken from UKPDS given the lack of Polish data.
Measure of benefit:
Quality-adjusted life-years (QALYs) and life-years were used as the summary benefit measures and were discounted at an annual rate of 3.5%.
